N※N

Torrent Pharma Appoints New CTO for Digital Transformation

  //science-technology.news-articles.net/content/2 .. appoints-new-cto-for-digital-transformation.html
  Published in Science and Technology on Sunday, February 1st 2026 at 1:08 GMT by Daily
      Locales: Gujarat, Maharashtra, INDIA

Mumbai, India - February 1st, 2026 - Torrent Pharmaceuticals, a leading Indian pharmaceutical company, today announced the appointment of Geena Malhotra as its new Chief Technology Officer (CTO). Malhotra joins Torrent from Cipla, where she previously held the position of Global CTO, signaling a clear commitment by Torrent to prioritize digital transformation and technological innovation.

This strategic appointment isn't simply about filling a role; it represents a fundamental shift in how Torrent Pharma intends to approach the future of pharmaceutical development, manufacturing, and distribution. The industry is undergoing a rapid evolution, driven by advancements in artificial intelligence, machine learning, big data analytics, and the increasing need for personalized medicine. Torrent, like its competitors, recognizes that remaining competitive requires a robust technological backbone and a leader capable of architecting and implementing that vision.

Malhotra's background at Cipla, a global pharmaceutical powerhouse, is particularly noteworthy. During her tenure at Cipla, she spearheaded numerous digital initiatives, including the implementation of advanced data analytics platforms to optimize supply chain management, improve clinical trial efficiency, and enhance patient engagement. Sources close to Cipla suggest her team was instrumental in streamlining the company's R&D processes, reducing time-to-market for new generics and biosimilars. It is this proven track record of delivering tangible results that Torrent Pharma is hoping to replicate.

The pharmaceutical industry is increasingly reliant on technology to address complex challenges. Drug discovery, traditionally a lengthy and expensive process, is being revolutionized by AI-powered platforms capable of analyzing vast datasets to identify potential drug candidates and predict their efficacy. Manufacturing processes are becoming more automated and data-driven, ensuring higher quality and reducing costs. Furthermore, digital tools are enabling more effective patient monitoring and adherence programs, ultimately improving health outcomes.

Torrent Pharma's statement emphasized Malhotra's role in "driving Torrent Pharma's technology vision and strategy." This suggests the company isn't looking for simply an implementer of existing technologies, but a visionary leader capable of identifying and capitalizing on emerging trends. Analysts predict that Malhotra will likely focus on several key areas within Torrent, including:

• Digital R&D: Utilizing AI and machine learning to accelerate drug discovery, optimize clinical trials, and personalize medicine.
• Smart Manufacturing: Implementing advanced automation, robotics, and data analytics to improve manufacturing efficiency, reduce costs, and ensure product quality.
• Supply Chain Optimization: Leveraging blockchain technology and real-time data analytics to enhance supply chain visibility, traceability, and resilience.
• Patient Engagement: Developing digital platforms and tools to improve patient adherence, provide personalized support, and enhance the overall patient experience.
• Data Security & Compliance: Ensuring the secure and compliant management of sensitive patient data and intellectual property.

"Her expertise and proven track record in technology leadership will be invaluable as we continue to enhance our capabilities and drive innovation," the Torrent Pharma spokesperson stated. This highlights the company's proactive approach to embracing technology as a core component of its growth strategy.

Beyond internal improvements, the appointment suggests Torrent Pharma is preparing to compete more aggressively in the global pharmaceutical market. Increased efficiency and faster innovation cycles driven by digital technologies can translate into significant competitive advantages. Furthermore, the ability to leverage data effectively can allow Torrent to identify unmet medical needs and develop targeted therapies, strengthening its position as a leading healthcare provider.

The timing of this appointment is also significant. The pharmaceutical industry is facing increased pressure to reduce costs and improve outcomes while navigating complex regulatory landscapes. Technology offers a powerful toolkit for addressing these challenges, and Torrent Pharma appears determined to be at the forefront of this transformation. The industry will be watching closely to see how Malhotra's expertise translates into tangible results for Torrent Pharma and its stakeholders.